Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP14 | P50281 | 19/20 | 0.76 |
| ▸ | MMP13 | P45452 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6392878 | 0.88 | MMP14 (0.76) | MMP14MMP13 | |
| SCHEMBL6385860 | 0.86 | MMP14 (0.76) | MMP14MMP13 | |
| SCHEMBL23752315 | 0.85 | MMP14 (1.00) | MMP14MMP13 | |
| SCHEMBL6386922 | 0.83 | MMP14 (1.00) | MMP14MMP13 | |
| SCHEMBL6391958 | 0.83 | MMP14 (1.00) | MMP14MMP13 | |
| SCHEMBL6389057 | 0.83 | MMP14 (1.00) | MMP14MMP13 | |
| SCHEMBL6388821 | 0.82 | MMP13 (0.74) | MMP14MMP13 | |
| SCHEMBL6388193 | 0.81 | MMP13 (0.73) | MMP14MMP13 | |
| SCHEMBL6388181 | 0.81 | MMP13 (0.73) | MMP14MMP13 | |
| SCHEMBL6389586 | 0.81 | MMP13 (0.73) | MMP14MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107414-A1 | Pyrimidine-2,4,6-trione metalloproteinase inhibitors | NOE MARK C (US) | 2005-05-19 | — | — | US | disclosed |
| US-6706723-B2 | Pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER, INC. | 2004-03-16 | — | — | US | disclosed |
| EP-1332136-A2 | PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | Pfizer Products Inc. (US) | 2003-08-06 | — | — | EP | disclosed |
| WO-2002034726-A9 | PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | PFIZER PROD INC (US) | 2003-03-06 | — | — | WO | disclosed |
| WO-2002034726-A9 | PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | PFIZER PROD INC (US) | 2003-03-06 | — | — | WO | disclosed |
| US-20020132822-A1 | Pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER PRODUCTS INC. | 2002-09-19 | — | — | US | disclosed |
| WO-2002034726-A2 | PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107414-A1 | Pyrimidine-2,4,6-trione metalloproteinase inhibitors | TYMP, DPYD, TYMS | MMP14 65/4885MMP13 50/4885 |
| US-20020132822-A1 | Pyrimidine-2,4,6-trione metalloproteinase inhibitors | TYMP, DPYD, TYMS | MMP14 70/4885MMP13 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.